Recently, the Food and Drug Administration (FDA) began accepting electronic filings as standard submissions for the documentation of clinical drug trials. Historically, the FDA and other government agencies have insisted on paper documents, which have presented obstacles for drug makers wanting to automate and streamline their operations. My November 2008 article looks at the automation and technology options that the FDA's new electronic filing policy presents and how life sciences companies are transforming their processes in response.
http://www.managingautomation.com/maonline/magazine/read/view/Ending_the_Endless_Waves_of_Paper_238606

